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Background: Levetiracetam is a frequently used drug in the therapy of partial onset, myoclonic and generalized
tonic-clonic seizures. The main route of elimination is via the kidneys, which eliminate 66% of the unchanged drug as
well as 24% as inactive metabolite that stems from enzymatic hydrolysis. Therefore dose adjustments are needed in
patients with chronic kidney disease stage 5 D, i.e. patients undergoing dialysis treatment. In this patient population a
dose reduction by 50% is recommended, so that patients receive 250–750 mg every 12 hours. However “dialysis” can
be performed in using different modalities and treatment intensities. For most of the drugs pharmacokinetic data
and dosing recommendations for patients undergoing peritoneal dialysis are not available. This is the first report on
levetiracetam pharmacokinetics in a peritoneal dialysis patient.
Case presentation: A 73-y-old Caucasian male (height: 160 cm, weight 93 kg, BMI 36.3 kg/m2) was admitted with a
Glasgow Coma Scale of 10. Due to diabetic and hypertensive nephropathy he was undergoing peritoneal dialysis
for two years. Eight weeks prior he was put on levetiracetam 500 mg twice daily for suspected partial seizures with
secondary generalization. According to the patient’s wife, levetiracetam lead to fatigue and somnolence leading to
trauma with fracture of the metatarsal bone. Indeed, even 24 hours after discontinuation of levetiracetam blood level
was still 29.8 mg/l (therapeutic range: 12 – 46 mg/l). Fatigue and stupor had disappeared five days after
discontinuation of the levetiracepam. A single dose pharamockinetic after re-exposure showed an increased half life of
18.4 hours (normal half life 7 hours) and levetiracetam content in the peritoneal dialysate. Both half-life and dialysate
content might help to guide dosing in this patient population.
Conclusion: If levetiracetam is used in peritoneal dialysis patients it should be regularly monitored to avoid
supratherapeutic levels that could lead to severe sequelae.Background
Several guidelines list levetiracetam as the drug of first
choice for adult patients with partial seizures with or
without secondary generalization and as second choice for
patients in the epileptic status. Levetiracetam (molecular
weight 170.2 Da) is rapidly absorbed after oral ingestion
with bioavailability of almost 100%. Peak concentrations
are reached 1.3 hours after ingestion. Neither levetiracetam
nor its primary metabolites are bound to plasma proteins.
Its volume of distribution is 0.5 – 0.7 l/kg. The elimination
half-life in adults is 7 ± 1 hours. Only about a quarter of* Correspondence: kielstein@yahoo.com
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reproduction in any medium, provided the orthe dose is metabolised by enzymatic hydrolysis in the
blood. The cumulated renal excretion rate of levetiracetam
is 66% in the first 48 hours [1]. These pharmacokinetic
coordinates vividly illustrate that meticulous attention has
to be paid if patients with chronic kidney disease are
treated [2]. It has been advocated to decrease the dose in
parallel with the decline of the glomerular filtration rate
[1]. For patients “on dialysis” the package insert suggests a
dose of 500–1000 mg once a day. As the small unbound
molecule is easily removed by “dialysis” a supplemental
dose of 250–500 mg after dialysis is suggested. Despite the
fact that levetiracetam was approved 13 years ago, there
are no data for dosing in peritoneal dialysis patients. We
therefore analysed pharmacokinetic data of levetiracetamtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Levetiracetam pharmacokinetics after a single oral
dose of 500 mg. The two concentrations in the peritoneal dialysate
are depicted as triangles.
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Case presentation
A 73-y-old Caucasian male was admitted to our tertiary
care hospital to undergo elective angioplasty due to per-
ipheral artery disease Fontaine’s stage IV. Diabetic and
hypertensive nephropathy led to CK5D, i.e. chronic dialy-
sis. He had been undergoing peritoneal dialysis treatment
for two years. His past medical history included Insulin-
dependent Diabetes mellitus type II and heart failure New
York Heart Association stage III due to severe ischemic
cardiomyopathy. He was status post aortocoronary bypass
operation and had a cardioverter-defibrillator due to re-
current monomorphic ventricular tachycardia.
On admission the patient complained about fatigue
and stupor. His wife reported that that his agitated and
at times hostile temper had recently completely sub-
sided. Relieved at first, the wife of the patient was than
worried as this hallmark of his character had remained
constant since they met more than 50 years ago. A thor-
ough history revealed this new calm and at times sleepy
state coincided with the start of levetiracetam treatment.
The patient received a dose of 500 mg bid due to sus-
pected partial seizures with secondary generalization
eight weeks to the recent admission. A neurological
workup at that time showed however no pathological
findings. Due to the severe fatigue our patient stumbled
and fractured his metatarsal bone of his left digitus V a
week prior to admission.
On admission physical examination showed an obese
(height: 160 cm, weight 93 kg, BMI 36.3 kg/m2) patient
with a Glasgow Coma Scale of 10 and with ulcerations
of both legs. Neither popliteal, tibial nor peroneal pulses
were palpable. His blood pressure was 135/75 mmHg,
heart rate 65 bpm. He presented with anemia (hemoglobin
of 8.7 [13.5-17.5] g/dl) and an elevated c-reactive protein
of 46 [<8] mg/l. Percutaneous transluminal angioplasty
could be performed with good result and without com-
plication. As fatigue and drowsiness did not improve
over time, we assumed an overdosing of the antiepileptic
drug levetiracetam with typical symptoms of overdose,
particularly as vital signs, especially blood pressure, were
normal and evidence of cardiac instability were missing.
Twentyfour hours after discontinuation of levetiracetam
we found levetiracetam-levels still at about 29.8 mg/l
(therapeutic range: 12 – 46 mg/l). Five days after discon-
tinuation the level was at 2 mg/l. Unfortunately there
were neither blood samples at the time of trauma, nor
between discontinuation of the drug and day 5 after
discontinuation available, which would have allowed a
stronger conclusion in terms of causality. Clinically,
however fatigue and stupor had disappeared five days
after discontinuation of the levetiracepam. In order toestablish the assumed accumulation/overdose of leveti-
racetam we re-exposed the patient to the drug. After
discontinuing levetiracetam for 7 days, a single dose of
500 mg levetiracetam was administered after end of
automated peritoneal dialysis (APD). Blood was taken
before ingestion and at regular intervals until 24 hours
after ingestion as well as peritoneal fluid before ingestion
and 7.5 h and 20 h after ingestion in order to study
pharmacokinetics in peritoneal dialysis (Figure 1). Sam-
ples were centrifuged at 2800xg for 5 min at 4°C and
stored at −80°C until analysis. Levetiracetam levels were
measured using an HPLC method. In brief, after a
liquid-liquid extraction of 300 μl serum to eliminate
lipophile components the samples were applied to a
reversed phase HPLC with UV detection. The detection
limit of levetiracetam was 1 mg/l and the linearity of the
method was from 0–100 mg/l. Intra-assay CV was 3.1%
(pool serum with 15 mg/l; n = 10), Inter-assay precision
(n = 8) was 7.2% (15 mg/l), and 6% (30 mg/l), respect-
ively. Levetiracetam half life after a single oral dose of
500 mg was found to be 18.4 hours, which is more than
doubled as compared to patients with normal renal
function (half life 7 hours). Serum levels and peritoneal
fluid levels were nearly equivalent at two different time
period.
Conclusions
Drug dosing in patients with chronic kidney disease can
be a challenging task, especially for those drugs in
which neither a physiological readout (blood pressure)
nor laboratory data (blood glucose) are available. Peritoneal
dialysis is a rather infrequently used dialysis modality.
According to the 2012 USRDS report (www.usrds.org) less
than 30,000 patients in the US undergo peritoneal dialysis
as compared to 400,000 patients on hemodialysis, which is
below the global rate of 12% [3]. Choice of dialysis modality
is however very heterogenous and influenced by multiple
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rate of 0% in Luxemburg and a rate of 49% in New Zealand
among patients on maintenance dialysis [3]. In general, the
quantity of drugs removed during peritoneal dialysis is sub-
stantially lower than that during hemodialysis, and thus,
the supplemental administration of drugs, even when they
are efficiently removed during hemodialysis, is not neces-
sary in patients receiving continuous ambulatory peritoneal
dialysis (CAPD) [4]. There are only limited data on how
newer antiepileptic drugs are handled by the kidney and es-
pecially how the different modes and intensities affect those
drugs [5]. In a situation like this even a single case like ours
can enhance the quality of pharmacokinetic information
available to clinicians, as recently asked for by a KDIGO
working group [6]. Antiepileptic drugs are frequently used
in patients with renal impairment. Safe and effective treat-
ment requires attention to changes in pharmacokinetics
and knowledge about the effect of extracorporeal treatment
methods in terms of elimination of these drugs. Thera-
peutic drug monitoring can be a valuable aid [7]. For leveti-
racetam most individuals display optimal response to
treatment with trough serum levels 12 to 46 mg/l. Some in-
dividuals may respond well outside of this range, or may
display toxicity within the therapeutic range, thus interpret-
ation should include clinical evaluation [8]. Toxic levels
have not been well established but anecdotal reports show
that overdose is facilitated if chronic kidney disease is
present [9]. For patients in CKD 5 D, i.e. patient undergoing
dialysis PubMed (www.ncbi.nlm.nih.gov/pubmed) does not
list a single pharmacokinetic study. The package insert such
as reference books and online resources recommend a dose
of 250–500 mg bid and an additional dose of 250–500 mg
after “dialysis”.
Our data from a peritoneal dialysis patient suggest that
a dose as low as 500 mg bid has the potential of causing
severe side effects. As dosing guidelines for patients on
thrice weekly hemodialysis should not be simply trans-
ferred to patients undergoing daily peritoneal dialysis it
is also not understandable how some online-resources
advice to reduce the dose of levetiracetam in pediatric
peritoneal dialysis patients by 50%. Our case illustrates
that therapeutic drug monitoring should be used in this
patient population whenever possible. This opportunity
was missed in the reported case and could probably have
avoided the severe side effects of the levetiracepam
overdose.
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